1st Counsel – Lifestyle
Author:
Arch Biopartners
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
April 30, 2026
Arch Biopartners Closes Non-Brokered Private Placement
April 2, 2026
Arch Biopartners Arranges Non-Brokered Private Placement
March 30, 2026
Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial
March 24, 2026
Arch Biopartners Announces St. Michael’s Hospital Commences Patient Dosing in the Phase II CS-AKI Trial of LSALT Peptide
March 20, 2026